Bayer AG
376 articles with Bayer AG
-
Celmatix Achieves Milestone for PCOS Drug Program
1/18/2022
Celmatix Inc., a biotechnology company focused on ovarian biology, announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec.
-
Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology
1/10/2022
Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.
-
The cash came rolling in for four biopharma companies Thursday morning, with collective Series A rounds totaling more than $125 million.
-
Effective January 1, 2022: Rodrigo Santos Named Member of the Board of Management, Bayer AG, and President of the Crop Science Division
11/9/2021
The Supervisory Board of Bayer AG has appointed Rodrigo Santos to the company’s Board of Management and the position of President of the Crop Science division, effective January 1, 2022.
-
Redosing is a large and growing concern for gene therapy developers and regulators.
-
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
-
BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225
9/16/2021
BWX Technologies, Inc. announced that its BWXT Medical Ltd. subsidiary has entered into an agreement with Bayer AG to develop Actinium-225 supply and further partnering opportunities on finished products as both companies broaden their respective commercialization strategies for targeted radionuclide therapies and other innovative products.
-
Versant Ventures Announces Acquisition of Portfolio Company Vividion Therapeutics
8/5/2021
Versant Ventures announced that portfolio company Vividion Therapeutics has been acquired by Bayer AG for $1.5 billion up front and up to $500 million in potential future milestone payments.
-
Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics
8/5/2021
Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform
-
Under the terms of the agreement, Bayer is paying $1.5 billion upfront and up to $500 million in various milestone payments.
-
Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease
6/8/2021
Bayer is pursuing a two-pronged approach to deliver transformative therapies with one cell and one gene therapy candidate in clinical trials.
-
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
5/26/2021
Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials
-
BioSpace takes an in-depth look at the Top 25 of Q1.
-
The filing to the U.S. District Court District of New Jersey, dated December 31st, 2020, states that the materials include compound data, strategic plans related to translational and biomarker data, therapeutic program reviews, abstract publications, plans for Congressional presentations, drug mo...
-
Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy
10/26/2020
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need
-
Leaps by Bayer Leads USD 17 Million Series B Financing in Biotech Company Azitra
10/15/2020
Harnessing the human skin microbiome to develop cutting-edge solutions moving the paradigm from treatment to cure in dermatology
-
Vincera Pharma, Inc Announces Exclusive License Agreement for Oncology Portfolio Including a Clinical-stage PTEFb/CDK9 Inhibitor and a Preclinical Bioconjugation Platform
10/8/2020
P ortfolio includes VIP152, a highly selective PTEFb /CDK9 inhibitor with encouraging Phase 1 monotherapy activity , including complete responses in DH-DLBCL Vincera intends to pursue multiple accelerated approval opportunities in M YC - and MCL1- driven cancers Preclinical bioconjugation platform designed to overcome limitations of small - molecule and antibody - drug conjugates use to treat cancer SANTA CLARA, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE)
-
Bayer and Northpond Ventures Lead USD 55 million Series A Financing Round for Triumvira Immunologics
8/27/2020
Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments
-
Bayer and Temasek Unveil Innovative New Company Focused on Developing Breakthroughs in Vertical Farming
8/12/2020
Called Unfold, the new company will be headquartered in the Davis, Calif., area with key operations in both the U.S. and Singapore
-
Bayer AG Standardizes on Veeva Vault Clinical Applications Globally
7/23/2020
Global life sciences leader selects Vault Study Startup and Vault eTMF to improve trial efficiency